Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 119

Similar articles for PubMed (Select 11435263)

1.

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study.

Allgulander C, Hackett D, Salinas E.

Br J Psychiatry. 2001 Jul;179:15-22. Erratum in: Br J Psychiatry 2001 Aug;179:181.

2.
3.

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.

Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM.

Psychopharmacology (Berl). 2005 Jan;177(3):280-8. Epub 2004 Jul 16.

PMID:
15258718
4.

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.

Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, Emilien G; SAD 388 Study Group.

Hum Psychopharmacol. 2004 Aug;19(6):387-96.

PMID:
15303242
5.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
6.
7.
8.

Efficacy and tolerability of long-term venlafaxine XR therapy for GAD. Results of long-term, double-blind, placebo-controlled studies.

Lydiard RB.

Postgrad Med. 1999 Nov;106(6 Suppl):17-23. doi: 10.3810/pgm.11.1999.suppl1.3.

PMID:
19667500
9.

Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.

Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ.

J Clin Psychopharmacol. 2006 Jun;26(3):259-67. Erratum in: J Clin Psychopharmacol. 2006 Oct;26(5):473. Dosage error in article text.

PMID:
16702890
11.

The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.

Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RM, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT.

J Clin Psychiatry. 2007 Aug;68(8):1246-56.

PMID:
17854250
12.

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

Rickels K, Pollack MH, Sheehan DV, Haskins JT.

Am J Psychiatry. 2000 Jun;157(6):968-74.

PMID:
10831478
13.

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study.

Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G.

Int Clin Psychopharmacol. 2004 Nov;19(6):331-6.

PMID:
15486518
14.
15.

A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.

Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B.

Depress Anxiety. 2007;24(1):1-14.

PMID:
16894619
16.
17.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
18.
19.

Venlafaxine XR in the treatment of anxiety.

Hackett D.

Acta Psychiatr Scand Suppl. 2000;(406):30-5.

PMID:
11131468
20.

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.

J Clin Psychiatry. 2006 Jan;67(1):72-80.

PMID:
16426091
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk